Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs OCALIVA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
The terminal elimination half-life of obeticholic acid is approximately 24 hours for the parent drug and 3.5 to 5.8 days for its active conjugates (glyco- and tauro-obeticholic acid). This long half-life supports once-daily dosing but indicates that steady-state is reached after about 2 weeks.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Obeticholic acid is metabolized in the liver and intestine via conjugation with glycine or taurine, and subsequently undergoes extensive enterohepatic recirculation. It is not significantly metabolized by CYP450 enzymes. The conjugated metabolites are eliminated in feces.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Following oral administration, approximately 87% of the dose is excreted in feces (primarily as unchanged drug and metabolites) and less than 3% is excreted renally. Biliary excretion is the major route for the parent drug and its conjugates.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Obeticholic acid is approximately 99% bound to plasma proteins, primarily albumin.
4-6 L/kg; large Vd indicates extensive tissue distribution
The volume of distribution is approximately 6.5 L/kg, indicating extensive extravascular distribution, consistent with its lipophilic nature and high tissue binding, particularly to liver and intestinal tissues.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Absolute bioavailability of oral obeticholic acid is approximately 50%, with a range of 30-70% due to first-pass hepatic metabolism and conjugation.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (e GFR <30 m L/min/1.73 m2).
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh class A: No adjustment. Child-Pugh class B: Initial dose 5 mg once daily, increase to 10 mg if tolerated. Child-Pugh class C: Contraindicated.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Safety and efficacy not established in pediatric patients.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment; use caution due to potential for increased exposure and hepatic impairment.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
WARNING: HEPATIC DECOMPENSATION AND LIVER FAILURE IN INCORRECTLY DOSED PBC PATIENTS WITH CHILD-PUGH CLASS B OR DECOMPENSATED CIRRHOSIS. Patients with Child-Pugh class B or decompensated cirrhosis (Child-Pugh class C) are at increased risk of hepatic decompensation and liver failure when incorrectly dosed. Ocaliva is contraindicated in patients with decompensated cirrhosis (Child-Pugh class C). In patients with Child-Pugh class B, the starting dose is 5 mg once weekly, with dose adjustment based on response and tolerability.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hepatic decompensation and liver failure in patients with Child-Pugh class B or decompensated cirrhosis,Risk of hepatic decompensation in patients with moderate to severe hepatic impairment,Severe pruritus: dose reduction, antihistamines, or bile acid resins may be considered,Reduction in HDL-C levels; monitor lipid levels periodically,Monitor liver function tests (e.g., bilirubin, INR) and signs of hepatic decompensation
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class C),Known hypersensitivity to obeticholic acid or any component of the formulation
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No specific food restrictions; however, consistent administration with or without food is recommended. Avoid grapefruit juice as it may increase drug exposure. Limit alcohol consumption to reduce liver stress.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits during organogenesis at doses less than the maximum recommended human dose (MRHD) resulted in embryofetal mortality and malformations. Based on animal data, Ocaliva may cause fetal harm when administered to a pregnant woman. Avoid use during pregnancy, especially in the first trimester, unless the potential benefit to the mother outweighs the potential risk to the fetus.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
It is not known whether obeticholic acid is excreted in human milk. In animal studies, obeticholic acid and/or its metabolites were detected in milk of lactating rats. The M/P ratio is not available. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Ocaliva, women should not breastfeed during treatment and for 3 weeks after the last dose.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dose adjustments for pregnancy are provided in the labeling. Ocaliva is contraindicated in patients with complete biliary obstruction, and use during pregnancy should be avoided. If use is essential, no data exist to guide dose modifications; pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate empiric dose adjustment, but no formal studies have been conducted.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
OCALIVA (obeticholic acid) is a farnesoid X receptor agonist for primary biliary cholangitis (PBC). Monitor liver function tests closely; dose adjustments needed in moderate to severe hepatic impairment (Child-Pugh B or C). Titrate from 5 mg to 10 mg based on tolerability after 3 months. Contraindicated in patients with complete biliary obstruction. Pruritus is common; consider antihistamines or bile acid binders. Check INR if on warfarin due to potential interaction.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take with or without food, but be consistent with meals to maintain stable drug levels.,Do not stop or change dose without consulting your healthcare provider.,Report severe itching, jaundice, or dark urine immediately.,Avoid alcohol and medications that can harm the liver.,Inform all healthcare providers you are taking this medication.,Attend regular blood tests to monitor liver function and treatment response.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs OCALIVA, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. OCALIVA is a Farnesoid X receptor agonist that works by Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces the production of bile acids by suppressing cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and increases the expression of FXR target genes involved in bile acid transport and detoxification.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and OCALIVA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of OCALIVA is: 5 mg orally once daily, increase to 10 mg once daily if adequate response after 3 months.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and OCALIVA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. OCALIVA is classified as Category C. There are no adequate and well-controlled studies of Ocaliva in pregnant women. In animal reproduction studies, oral administration of obeticholic acid to pregnant rats and rabbits. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.